NICE recommends EYLEA for visual impairment due to diabetic macular oedema (DMO)
The National Institute for Health and Care Excellence (NICE) draft Final Appraisal Determination (FAD) recommends EYLEA for the treatment of patients with visual impairment due to diabetic macular...